{
  "id": 2393353,
  "title": "Merck stock analysis: great pipeline at a stretched valuation",
  "url": "https://urgent.news/2026/08/21/merck-stock-analysis-great-pipeline-at-a-stretched-valuation",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T14:47:46.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/merck-stock-analysis-great-pipeline-at-a-stretched-valuation-93CH-4871868"
  },
  "original_language": "en",
  "account": "Merck's stock has hit an all-time high of $153.53, marking a 78% increase over the past year, primarily driven by a positive Phase 3 readout for an mRNA cancer therapy developed jointly with Moderna. However, the stock is presently trading 7.5% above its fair value estimate, with a daily RSI of 78.4, indicating an overbought condition. The main catalyst behind the rally is the INTerpath-001 Phase 3 trial for Merck and Moderna's innovative mRNA melanoma treatment, the first of its kind to achieve positive Phase 3 results. Goldman Sachs has raised its price target to $160 from $140, maintaining a Buy rating, while UBS has downgraded the stock to Neutral at $150, citing the recent surge. Merck's growth trajectory has been impressive, with revenue rising from $48.7 billion in 2021 to $65.0 billion in 2025, and EPS increasing from $5.14 to $7.28 over the same period. The company's ROE stands at 36.9%, and its beta is 0.21, indicating low volatility. However, the looming patent cliff of Merck's blockbuster drug Keytruda, set to expire in 2029, poses a significant challenge, as generic competition will erode a substantial portion of its revenue. Despite the optimism surrounding the groundbreaking mRNA platform and the pipeline's potential, the current valuation is high, and investors may want to wait for a pullback or further pipeline readouts to de-risk the investment.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}